Home > Information > Press Release
Press Release
- Dec. 12, 2024
- Launch of "TMC Japan BioBridge / JACT Program"
- Nov. 5, 2024
- NCC will initiate new research to develop a nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for cancer patients.
- Sep. 20, 2024
- HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval
- Sep. 17, 2024
- SCRUM-Japan GOZILA Confirms Extended Survival with Personalized Cancer Treatment in 4,000+ Patients Study
- Sep. 17, 2024
- CIRCULATE-Japan GALAXY Confirms Effectiveness of Liquid Biopsy in Predicting Recurrence Risk and Post-operative Treatment Efficacy in Colorectal Cancer
- Sep. 12, 2024
- Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
- Aug. 9, 2024
- Start of Fecal Microbiota Transplantation Clinical Study for Esophageal and Gastric Cancer Patients
- Jul. 11, 2024
- Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
- Jun. 11, 2024
- Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System
- Jun. 4, 2024
- NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
- May 14, 2024
- World’s Largest Whole Genome Sequencing of Renal Cancer:
mutational signature linked to an unknown exposure discovered in 70% of Japanese samples - May 8, 2024
- Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure
- Jan. 15, 2024
- Result of a Japan-led International Investigator-Initiated Registration-Directed Trial Offers a New Treatment Option of Palbociclib in Combination with Tamoxifen
- Jan. 12, 2024
- Team explores role of STING – stimulator of interferon genes – in body’s innate immune system
- Jan. 11, 2024
- An Asian Multicenter Clinical Trial Evaluating Efficacy of
Computer-Aided Detection for Colonoscopy in Colorectal Cancer Screening - Dec. 14, 2023
- National Cancer Center Japan and Japan Investment Corporation (JIC) sign agreement to promote comprehensive collaboration
- Dec. 1, 2023
- Sharing of clinical trial information improves the quality of treatment recommendations by expert panels
- Nov. 29, 2023
- Molecular Mechanisms of Chromosomal Instability and Anti-Tumor Immune Activation Induced by DNA Replication Stress
- Sep. 20, 2023
- Research agreement on CAR-T cancer treatment development concluded between National Cancer Center and Asahi Kasei
- Aug. 14, 2023
- Carcinogenesis mechanism of gastric cancer discovered with whole genome sequencing
- Jun. 27, 2023
- Memorandum of Cooperation on Decentralized Clinical Trials between the Department of Medical Services and the National Cancer Center Japan.
- Jun. 12, 2023
- Announcing the approval of the apolipoprotein A2 isoform index for in vitro diagnostics in Japan
- Apr. 19, 2023
- World-first confirmation of standard treatment for RAS wild-type colorectal cancer－Paper published in JAMA－
- Apr. 12, 2023
- Start of Clinical Research of the First Japanese-Produced Next-Generation Photon Counting Computed Tomography
- Apr. 10, 2023
- Efficacy of Anti-HER2 Therapy with Trastuzumab Deluxecan in Uterine Carcinosarcoma Consistent with PDX-model predictions of efficacy, paving the way for the development of treatments for rare cancers.
- Apr. 3, 2023
- A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard treatment or which is refractory to standard treatment using Patient-Proposed Healthcare Service (NCCH2214/ TURTLE trial) to improve drug access for pediatric and AYA patients with refractory tumors.
- Mar. 14, 2023
- World’s Largest Gastric Cancer Genomic Study Reveals Treatment Targets for Japanese Patients Alcohol intake link gives hope for improving prevention strategies
- Feb. 28, 2023
- Questionable practices identified by an examination of therapeutic plan reviews performed by certified committees under the Act on the Safety of Regenerative Medicine
- Jan. 24, 2023
- Clinical Utility of Circulating Tumor DNA After Surgery for Colorectal Cancer Demonstrated in a Large-Scale Prospective Study －A Step toward Personalized Postoperative Adjuvant Chemotherapy－
- Jan. 5, 2023
- Moonshot Research and Development Program ‘Actualization of a cancer-free society through regulation of chronic inflammation’ launched
- Dec. 8, 2022
- Asian multicenter prospective study (CHOICE study) to elucidate the pathogenesis of cholangiocarcinoma(including FGFR2-rearranged) launched
- Nov. 4, 2022
- Cancer Genomic Medicine in Japan Engages International Interest - Article Published on Cancer Discovery
- Oct. 7, 2022
- Fusion genes as drug resistance in EGFR mutant lung cancer
- Sep. 27, 2022
- Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform
- Sep. 27, 2022
- Study pinpoints origin of pediatric brain tumour and shows it may be preventable
- Aug. 24, 2022
- Large scale clinical trial for Neuroendocrine Carcinoma (NEC), a rare and refractory cancer establishes current chemotherapy for advanced and recurrent cancer as standard therapy
- Aug. 5, 2022
- Prospective Cohort Study demonstrates ESD as primary choice of treatment for neoplasia of over 2cm
- Aug. 4, 2022
- Approximately 43,000 individual patient data of clinical trials with colorectal cancer in Asia and the West shared
- Aug. 1, 2022
- First Japanese and Asian Chairperson of IARC Scientific Council
Dr. Manami Inoue, Chief – Institute for Cancer Control, NCC
Contributing to Global Cancer Control - Jul. 21, 2022
- Joint Research with IARC Identifying associations between lifestyle risk factors and the prognosis of cancer survivors
- Jul. 1, 2022
- Utility of gene panel testing for comprehensive genomic profiling of blood cancers demonstrated
- Mar. 3, 2022
- Discovery of splicing vulnerability and novel therapy in RAS Q61 cancers -Nature-
- Jan. 28, 2022
- Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
- Dec. 24, 2021
- Depletion of central memory CD8+T cells might impede the antitumor therapeutic effect of Mogamulizumab
- Dec. 23, 2021
- Launch of an Asian international collaborative prospective study on 6 advanced cancers common in Asia
- Dec. 21, 2021
- CLIP1-LTK fusion: A novel druggable gene fusion in NSCLC,
identified using LC-SCRUM-Asia genomic screening platform - Nov. 15, 2021
- Activated WNT/β-catenin pathway induces resistance to immunotherapies in cancers harboring high tumor mutation burden
- Nov. 12, 2021
- Study shows efficacy of dual-HER2 targeted therapy for patients with HER2-positive colorectal cancer
- Nov. 11, 2021
- First in-patient transplantation of iPS cell-derived natural killer cells to treat ovarian cancer
- Oct. 28, 2021
- Unveiling the Landscape of Genomic Alterations in Adult T-Cell Leukemia/Lymphoma
- Oct. 27, 2021
- Global whole genome sequencing research on esophageal cancers reveals
carcinogenic mechanisms specific to Japan - Oct. 20, 2021
- MASTER KEY ASIA
- Oct. 14, 2021
- Breakthrough Discovery on the Structure and Activation Mechanism of ALK
- Sep. 6, 2021
- Molecular landscape of multi-step virus carcinogenesis revealed by multi-modal single-cell analysis
- Aug. 17, 2021
- Whole Genome Sequencing Finds Therapeutic Targets for Linitis Plastica-type Gastric Cancer
- Jun. 30, 2021
- Initiation of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan, SCRUM-Japan
- Jun. 2, 2021
- SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan
- May 17, 2021
- "MONSTAR-SCREEN" has joined as an official member program in the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC-ARGO)
- May 14, 2021
- NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
- Apr. 27, 2021
- National Cancer Center Japan and Pharmaceuticals and Medical Devices Agency Endorsed as a joint Center of Excellence by APEC
- Mar. 23, 2021
- First drug approved for unresectable thymic carcinoma
- Feb. 2, 2021
- Deep Vision: Near-Infrared Imaging and Machine Learning Can Identify Hidden Tumors
- Oct. 6, 2020
- Development of Precision Medicine for Gastrointestinal Cancers Utility of Liquid Biopsy in Genomic Analysis
- Sep. 9, 2020
- Asian early phase drug development network
ATLAS Project – Paving the way towards developing drugs with Asian partners - Sep. 1, 2020
- A novel biomarker for predicting clinical efficacy of PD-1 blockade therapies
- Jul. 3, 2020
- The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
- Jun. 22, 2020
- National Cancer Center Japan and Mitsui Fudosan Agree on Accommodation Facility at the National Cancer Center Hospital East in Kashiwa-no-ha Smart City
- Apr. 1, 2020
- Advanced Medical Care Approval for Cancer Gene Panel Testing at the Time of Initial Treatment
- Prospective Study to Assess the Feasibility and Clinical Utility of Comprehensive Genomic Profiling at the Time of Initial Treatment of Patients with Solid Tumors - - Feb. 17, 2020
- Global Consortium Completes Tumor Analyses Project
- Dec. 11, 2019
- Test Result of New Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting Proves Higher Efficacy Than Standard Antiemetic Therapy
- May 29, 2019
- Cancer Gene Panel Test OncoGuideTM NCC Oncopanel System added to Health Insurance Coverage list
- Mar. 26, 2019
- Launch a joint research project on a new cancer immunotherapy using liposome, a drug delivery system technology
－Goal is to identify its actions on immune cells, and elucidate the mechanism by which survival periods are extended－ - Nov. 12, 2018
- Facilitating International Clinical Trials Initiated by
Japanese Academic Institutions
Japan-led Global Investigator-Initiated Registration-Directed Trial of Advanced or Metastatic Breast Cancer (PATHWAY trial) Has Started - Oct. 1, 2018
- National Cancer Center Japan and Maruho Enter License Agreement and Research Collaboration Agreement for a Novel Analgesic for Stomatitis in Cancer Treatment
- Jun. 27, 2018
- Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma
- Jun. 1, 2018
- NCC Establishes Center for Cancer Genomics and Advanced
Therapeutics (C-CAT) to Aggregate and Manage Information on
Cancer Genomic Medicine and Promote Its Use - May 7, 2018
- National Cancer Center and Carna Biosciences Announce Research Collaboration for new drug discovery
- Apr. 3, 2018
- National Cancer Center Hospital offers Next Generation Sequencing tests as ‘Advanced Medical Care’
Towards coverage under national health insurance system - Apr. 3, 2018
- Advanced Medical Care Approval Received for Multiplex Gene Panel Testing
to Advancing Personalized Medicine - Mar. 13, 2018
- SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood
- Feb. 14, 2018
- A secondary RET mutation in the activation loop conferring
resistance to vandetanib through allosteric effects - Jan. 23, 2018
- Precise cancer risk estimation based upon measurement of mutations and aberrant DNA methylation accumulated in normal tissues
association between the accumulation and life style - Dec. 22, 2017
- T. Matsuda takes office of International Association of Cancer Registries President
- Dec. 5, 2017
- NCC signs comprehensive MoU with WHO/IARC
- Nov. 27, 2017
- Asian Early Phase Oncology Drug Development Consortium Formed
- Oct. 27, 2017
- Collaborative Research on Fully-personalized Cancer Neoantigen Vaccine
- Oct. 16, 2017
- Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
- Aug. 3, 2017
- Japan-Singapore lead international research in discovering potential targeted treatments for biliary tract cancer
- Jul. 31, 2017
- The MASTER KEY PROJECT
Genomic medicine in Rare Cancers:
A collaboration between the industry and academia - Jun. 26, 2017
- A novel biomarker for development of a new screening technique for early-stage pancreatic cancer and precancerous conditions associated with risk of pancreatic malignancy - experimental screening in Kagoshima Prefecture
- May 30, 2017
- WHO/International Agency for Research on Cancer establishes National Cancer Center as Global Initiative for Cancer Registry Development Collaborating Centre
- Apr. 27, 2017
- Elucidation of the mechanism of MLL-rearranged leukemia Use of two molecularly targeted drugs as novel therapy
- Mar. 1, 2017
- Commencement of Phase 1 Trial for the Mutant IDH1 Inhibitor (DS-1001)Targeting Malignant Brain Tumors
- Feb. 28, 2017
- Malignant extracellular vesicles derived from ovarian cancer cells facilitate peritoneal dissemination, and the vesicles can be promising targets for improving patient outcomes.
- Feb. 21, 2017
- Signing MOU with the National Cancer Research Institute (UK)
- Jan. 1, 2017
- Press Release:Joint R&D with the Goal of Commercialization of a Scaled-Down,Methylated DNA Detection Device for Renal Cell Carcinoma Prognostication,and Other Cancers,by 2018.
- Jan. 1, 2017
- Press Release:Signing MOU with the Institut National du Cancer (French National Cancer Institute)
- Jan. 1, 2017
- Press Release:National Cancer Center of Japan and Takeda Partner to Discover Anti-Cancer Agents
- Jan. 1, 2017
- Development of a Novel Nucleic Acid Drug Discovered by National Cancer Center
- Dec. 21, 2016
- New Risk Diagnosis Technique for Additional Gastric Cancer After Endoscopic Curative Treatment of A Gastric Cancer